Form D · Biotechnology
Causeway Therapeutics Ltd
Glasgow, X0 · CIK 0001966914
Offering snapshot reported Feb 28, 2023 · SEC filing
- Reported sold
- $14.3M Offering amount: $14.3M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 3, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 28, 2023 | Initial | $14,263,627 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-474432
Source: Form D, filed Feb 28, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Armour | Executive |
| Gregor Caldow | Director |
| Declan Doogan | Director |
| Neil Gibson | Director |
| Derek Gilchrist | Director, Executive |
| Christopher Jones | Director |
| Neal Millar | Executive |
| Alexander Picket | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Imaging Centre Of Excellence Queen Elizabeth University Hospital
Glasgow, X0, G51 4TF
Glasgow, X0, G51 4TF